Myopia (nearsightedness) is a global public health crisis. By 2050, nearly 5 billion people or 1 out of every 2 people on earth will suffer from myopia. In the USA, myopia cases have increased 66% since 1971. Today in East and Southeast Asia in countries such as South Korea, Taiwan, Singapore, China and Japan the prevalence of myopia is 80-90% among urban teenagers. 

Looking forward, our comfortable, motion insensitive CXL will give TECLens the ability to treat young children with qCXL for control of myopia progression. The same center-distance corneal shape used for presbyopia can reduce the peripheral hyperopia that drives myopia progression while eliminating the underlying myopic error, potentially freeing millions of young patients from spectacle dependency and the risks of pathologic myopia.  Orthokeratology and biofocal contact lens are being used for this today, but these techniques require years of daily compliance to lens use and care which can be very challenging with young children.  We believe that CXL can offer a permanent one-time treatment to reduce in peripheral hyperopic defocus and stop kids from significant myopia progression.